Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
10.1016/j.steroids.2014.05.002 54 JunF.YaminL.XinliX.ZheL.MinZ.BoZ.et al (2012)
This product is sold exclusively for in vitro and laboratory research purposes
Section 4: other pharmacological approaches to treat DKD Patients living with DKD often display neurohormonal hyperactivity, which elevates their risk for adverse CVD and renal outcomes
El Benna N, Ouachtou K, Mahroug N, Abdelouafi A, Karkouri M
"We need more data on the long-term effects and other outcomes related to cardiovascular health, particularly in lower-risk individuals," says Eva Madrid, co-lead researcher from the Universidad de Valparaso, Chile
US$ 20.34
US$ 28.32
US$ 27.63
